Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-06
2010-06-29
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S329000
Reexamination Certificate
active
07745411
ABSTRACT:
The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.
REFERENCES:
patent: 4987121 (1991-01-01), Baertschi et al.
patent: 5015629 (1991-05-01), diZerega et al.
patent: 5032507 (1991-07-01), Yu et al.
patent: 5104653 (1992-04-01), Michalevicz et al.
patent: 5188828 (1993-02-01), Goldberg et al.
patent: 5378808 (1995-01-01), D'Andrea et al.
patent: 5482924 (1996-01-01), Royet et al.
patent: 5541158 (1996-07-01), Vance et al.
patent: 5610056 (1997-03-01), Nakahata
patent: 5629292 (1997-05-01), Rodgers et al.
patent: 5693616 (1997-12-01), Krstenansky et al.
patent: 5716935 (1998-02-01), Rodgers et al.
patent: 5824297 (1998-10-01), Iwata et al.
patent: 5834432 (1998-11-01), Rodgers et al.
patent: 5955430 (1999-09-01), Rodgers et al.
patent: 6083747 (2000-07-01), Wong et al.
patent: 6165978 (2000-12-01), Rodgers et al.
patent: 6239109 (2001-05-01), Rodgers et al.
patent: 6335195 (2002-01-01), Rodgers et al.
patent: 6566335 (2003-05-01), Rodgers et al.
patent: 6762167 (2004-07-01), Rodgers et al.
patent: 7288522 (2007-10-01), Rodgers et al.
patent: 2004/0120959 (2004-06-01), Tryggvason et al.
patent: WO 95/08337 (1995-03-01), None
patent: WO 95/08565 (1995-03-01), None
patent: WO 96/39164 (1996-12-01), None
patent: WO 98-32457 (1998-07-01), None
patent: WO 99-26644 (1999-06-01), None
patent: WO 99-31125 (1999-06-01), None
Kurt R. Reissmann, M.D., (1950),Blood, “Studies on the Mechanizm of Erythropoietic Stimulation in Parabiotic Rats During Hypoxia”, 8: pp. 349-357.
Allan Erslev, M.D., (1953),Blood, “Humoral Regulation of Red Cell Production”, 8: pp. 349-357.
Jerry L. Spivak, (1986),Int. J. Cell Cloning, “The Mechanism of Action of Erythropoietin”, 4: pp. 139-166.
K. Sawada, et al., (1987),The Journal of Clinical Investigtation, Inc., “Purification of Human Erythroid Colony-forming Units and Demonstration of Specific Binding of Erythropoietin”, 80: pp. 357-366.
T.S. Kickler, et al., (1988),J. Am. Med. Assoc., “Effect of Repeated Whole Blood Donations on Serum Immunoreactive Erythropoietin Levels in Autologous Donors”, 260; pp. 65-67.
Jaime Caro, et al., (1979),J. Lab. Clin. Med., “Erythropoietin Levels in Uremic Nephric and Anephric Patients”, 93: pp. 449-458.
Heinz W. Radtke, et al., (1979),Blood, “Serum Erythropoietin Concentration in Chronic Renal Failure: Relationship to Degree of Anemia and Excretory Renal Function” 54(4): pp. 877-884.
Manju Chandra, M.D., et al., (1988),J. Pediatr., “Relation of Serum Erythropoietin Levels to Renal Excretory Function: Evidence for Lowered Set Point for Erythropoietin Production in Chronic Renal Failure”, 113: pp. 1015-1021.
Joseph W. Eschbach, M.D., et al., (1988),American Journal of Kidney Diseases, “Recombinant Human Erythropoietin: Implications for Nephrology” 11: pp. 203-209.
Satya P. Kunapuli, et al., (1987),Circulation Research, “Molecular Cloning of Human Angiotensinogen cDNA andEvidence for the Presence of Its mRNA in Rat Heart” 60: pp. 786-790.
W.M. Clouston, et al., (1988),Genomics, “Molecular Cloning of the Mouse Angiotensinogen Gene”, 2: pp. 240-248.
Ryoichiro Kageyama, et al., (1984),Biochemistry, “Primary Structure of Human Preangiotensinogen Deduced from the Cloned cDNA Sequence”, 23: pp. 3603-3609.
Hiroaki Ohkubo, et al., (1983),Biochemistry, “Cloning and Sequence Analysis of cDNA for Rat Angiotensinogen”, 80: pp. 2196-2200.
Dinna N. Cruz, M.D., et al., (1996),American Journal of Kidney Diseases, “Angiotensin-Converting Enzyme Inhibitor Therapy in Chronic Hemodialysis Patients: Any Evidence of Erythropoietin Resistance?”, 28(4): pp. 535-540.
Hirikata, et al., (1986),Clin. Nephrol., “Participation of the Renin-Angiotensin System in the Captopril-Induced Worsening of Anemia in Chronic Hemodialysis Patients”, 26: pp. 27-32.
Anne B. Gould, et al., (1980),J. Lab. Clin. Med., “Interrelation of the Renin System and Erythropoietin in Rats”, 96: pp. 523-534.
Peter J. Conlon, et al., (1993),Transplantation, “The Beneficial Effect of Enalapril on Erythrocytosis After Renal Transplantation”, 56: pp. 217-219.
E.M. Anderson, et al., (1997),Biology of the Neonate, “Does Angiotensin Play a Role in Human Fetal Erythropoiesis?”, 71: pp. 194-197.
B.I. Shand, et al., (1995),Journal of Human Hypertension, “Effect of Losartan on Haematology and Haemorheology in Elderly Patients with Essential Hypertension: A Pilot Study”, 9: pp. 233-235.
Bruce A. Julian, et al., (1994),Kidney International, “Erythropoiesis After Withdrawal of Enalapril in Post-Transplant Erythrocytosis”, 46: pp. 1397-1403.
R.S. Gaston, et al., (1993),Transplantation Proceedings, “Enalapril: Safe and Effective Therapy for Posttransplant Erythrocytosis”, 25(1): pp. 1029-1031.
M.S. Islam, et al., (1990),Transplant Int., “Captopril Induces Correction of Postrenal Transplant Erythremia”, 3: pp. 222-225.
L. Rostaing, et al., (1994),Transplantation Proceedings, “Erythrocytosis After Renal Transplant: Study of Erythroid Progenitors and Response to Enalapril”, 26(1): pp. 280-281.
Michal Mrug, et al., (1997),The American Society for Clinical Investigation, Inc., “Angiotensin II Stimulates Proliferation of Normal Early Erythroid Progenitors”, 100(9): pp. 2310-2314.
Fisher, et al., (1968),Annals New York Academy of Sciences, “Effects of Angiotensin, Norepinephrine and Renal Artery Constriction on Erythropoietin Production”, pp. 308-317.
James W. Fisher, et al., (1967),The Journal of Pharmacology and Experimental Therapeutics, “Effects of Angiotensin and Renal Artery Constriction on Erythropoietin Production”, 157(3): pp. 618-625.
D.L. Mann, et al., (1966),P.S.E.B.M., “Effect of Renin, Angiotensin II and Aldosterone on Erythropoiesis”, 121: pp. 1152-1154.
Yilmaz C. Bilsel, et al., (1963),P.S.E.B.M. “Angiotensin II and Erythropoiesis”, 114: pp. 475-479.
Ferrario, et al., (1998),J. Am. Soc. Nephrol., “Novel Angiotensin Peptides Regulate Blood Pressure, Endothelial Function, and Natriuresis”, 9: pp. 1716-1722.
Shridhar N. Iyer, et al., (1998),Hypertension, “Vasodepressor Actions of Angiotensin-(1-7)Unmasked During Combined Treatment with Lisinopril and Losartan”, 31: pp. 699-705.
Freeman, et al., (1996),Hypertension, “Angiotensin-(1-7)Inhibits Vascular Smooth Muscle Cell Growth”,28: p. 104-108.
Philipp Ambühl, et al., (1994),Brain Research Bulletin, “[7-D-ALA]-Angiotensin-(1-7):Selective Antagonism of Angiotensin-(1-7)in the Rat Paraventricular Nucleus”, 35(4): pp. 289-291.
Speth and Kim, (1990),BBRC, “Discrimination of Two Angiotensin II Receptor Subtypes with a Selective Agonist Analogue of Angiotensin II, p-Aminophenylalanine6Angiotensin II”, 169: pp. 997-1006.
Rose-Marie Catalioto, et al., (1994),European Journal of Pharmacology, “Angiotensins Induce the Release of Prostacyclin from Rabbit Vas Deferens: Evidence for Receptor Heterogeity”, 256: pp. 93-97.
Susan E. Bryson, et al., (1992),European Journal of Pharmacology, “Induction of the Angiotensin AT2Receptor Subtype Expression by Differentiation of the Neuroblastoma X Glioma Hybrid, NG-108-15”, 225: pp. 119-127.
Josef Pfeilschifter,et al., (1992),Europ
diZerega Gere
Rodgers Kathleen
Gupta Anish
McDonnell Boehnen & Hulbert & Berghoff LLP
University of Southern California
LandOfFree
Methods for promoting erythropoiesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for promoting erythropoiesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for promoting erythropoiesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213696